Literature DB >> 17148721

Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.

Charles L Bennett, Cara Angelotta, Paul R Yarnold, Andrew M Evens, Jeffrey A Zonder, Dennis W Raisch, Paul Richardson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17148721     DOI： 10.1001/jama.296.21.2558-c

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  46 in total

Review 1.  Pulmonary toxicities from targeted therapies: a review.

Authors:  Nicholas A Barber; Apar Kishor Ganti
Journal:  Target Oncol       Date:  2011-11-11       Impact factor: 4.493

2.  Cardiovascular endocrinology: Risk of venous thromboembolism with glucocorticoids.

Authors:  John A Heit
Journal:  Nat Rev Endocrinol       Date:  2013-05-28       Impact factor: 43.330

3.  Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia.

Authors:  Georg Aue; Jay Nelson Lozier; Xin Tian; Ann M Cullinane; Susan Soto; Leigh Samsel; Philip McCoy; Adrian Wiestner
Journal:  Am J Hematol       Date:  2011-08-02       Impact factor: 10.047

4.  [The use of erythropoiesis-stimulating proteins in anemic patients with malignant diseases].

Authors:  Heinz Ludwig; Thomas Auberger; Otto Ch Burghuber; Michael Gnant; Georg Hopfinger; Ulrich Jäger; Felix Keil; Gabriela Kornek; Werner Linkesch; Edgar Petru; Robert Pirker; Elisabeth Pittermann; Alexander Reinthaller; Hellmut Samonigg; Günther Steger; Felix Stockenhuber; Michael Studnicka; Günter Weiss; Christoph Zielinski
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

5.  Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.

Authors:  Sigurdur Y Kristinsson; Ruth M Pfeiffer; Magnus Björkholm; Lynn R Goldin; Sam Schulman; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2010-03-18       Impact factor: 22.113

6.  Venous thromboembolic disease.

Authors:  Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

7.  The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2).

Authors:  Lalitha Nayak; Hong Shi; G Brandon Atkins; Zhiyong Lin; Alvin H Schmaier; Mukesh K Jain
Journal:  Blood       Date:  2014-04-25       Impact factor: 22.113

8.  Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.

Authors:  Rachel Rosovsky; Fangxin Hong; Deanna Tocco; Brendan Connell; Constantine Mitsiades; Robert Schlossman; Irene Ghobrial; Leslie Lockridge; Diane Warren; Gary Bradwin; Mary Doyle; Nikhil Munshi; Robert J Soiffer; Kenneth C Anderson; Edie Weller; Paul Richardson
Journal:  Br J Haematol       Date:  2012-12-13       Impact factor: 6.998

Review 9.  Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?

Authors:  A Maraveyas; M Johnson
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

Review 10.  A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma.

Authors:  Marie von Lilienfeld-Toal; Corinna Hahn-Ast; Kerstin Furkert; Florian Hoffmann; Ralph Naumann; Ralf Bargou; Gordon Cook; Axel Glasmacher
Journal:  Eur J Haematol       Date:  2008-07-10       Impact factor: 2.997
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.